The opening day's sessions at BIO Asia-Taiwan 2024 on 26 July in Taipei, attracted a wide range of biotech professionals from Asia and around the world. Investment Summit was one of three tracks that comprised the newly-expanded conference program of this year's event. Despite the typhoon bearing down on the island, 48 preselected fund-seeking entities presented their investment pitches to 50 representatives of domestic and foreign investment houses. Taiwan Bio-Industry Organization (Taiwan BIO) co-organizers of BIO Asia–Taiwan stated that Taiwan's new biotechnology companies have attracted a growing investor interest, which has expressed optimism about the country's solid scientific foundation and the innovative spirit of the industry.

Both domestic and foreign biotech companies were invited to join the selection process for a chance to attend the Investment Summit in the months leading up to the event. A total of 48 companies from the United States, Canada, the United Kingdom, Japan, Switzerland, South Korea, Lithuania, Slovenia, and Taiwan were selected in such fields as drug development, digital health, medical imaging and artificial intelligence.

A large number of international venture capital firms participated in this inaugural event from countries including Japan, the United States, Taiwan, Singapore, Switzerland, the United Kingdom, Israel and attended the conference. Among the representatives are Flagship Pioneering, Illumina Ventures, Syncona, Prime Ventures, Vivo Capital, Israel's largest pharmaceutical venture capital fund aMoon; Pegasus Tech Ventures, Silicon Valley's third largest venture capital firm; Japan's DCI Partners; and Axil Capital Partners; providing the opportunity for participating companies to secure the funding they need to grow.

Audrey Tseng, Vice Chair of Taiwan BIO, coordinated the inaugural Investment Summit. She pointed out that Taiwan has a number of competitions for startups, but this event was focused on attracting companies seeking post-Series A investment, something most other events don't emphasize.

Additionally, Tseng mentioned that participating investment institutions were impressed with Taiwan's emerging biotech industry and its companies' solid scientific research foundations and innovation energy. For Taiwan's companies to succeed, Tseng also suggested improving their competitiveness and positioning in the market.

It is expected that BIO Asia–Taiwan will cement itself as Asia's No. 1 biotechnology investment destination with its excitement around this new event, one-on-one business partnership meetings, and other opportunities for both the investment community and the investment-seeking community to engage. 

Taiwan companies participating in this investment forum included: FaceHeart Corp, Hcmed, Health2Sync, JelloX Biotech, Point Robotics MedTech, Academab Biomedical, Acepodia, Elixiron Immunotherapeutics, Allgenesis Biotherapeutics, AnHorn Medicines, AnnJi Pharmaceutical , AP Biosciences, Apexcella Biomedical, HanchorBio, Immunwork, Lumosa Therapeutics, OBI Pharma, REGiMMUNE, Rock BioMedical, TFBS Bioscience, TriArm, TWi Biotechnology, Xgene Pharmaceutical,and others.